XTL Biopharmaceuticals (XTLB) wins back Nasdaq listing, faces 1-year watch

Rhea-AI Filing Summary

XTL Biopharmaceuticals Ltd. received confirmation from Nasdaq that it has regained compliance with four listing standards: the Public Interest Concern Rule, Periodic Filing Rule, Bid Price Rule, and Equity Rule, as required by a Nasdaq Hearings Panel decision dated May 4, 2026.

Nasdaq’s determination was based on the company maintaining a closing bid price above $1.00 for at least 20 consecutive trading days as of July 13, 2026, filing its Form 20-F for the year ended December 31, 2025 on June 30, 2026, and holding at least $2.5 million in stockholders’ equity after acquiring Psyga Bio Ltd. and raising equity capital. The company will be subject to a one-year Mandatory Panel Monitor; if it again falls out of compliance with the Equity Rule during this period, Nasdaq staff will issue a Delist Determination Letter without any additional plan or cure period, though the company may request a new hearing.

Positive

• Nasdaq confirmed the company has regained compliance with Listing Rules 5101, 5250(c)(1), 5550(a)(2), and 5550(b)(1), satisfying conditions set by the Nasdaq Hearings Panel.

Negative

• The company is under a one-year Mandatory Panel Monitor; any future Equity Rule deficiency during this period will lead Nasdaq staff to issue a Delist Determination Letter without an additional cure period.

Key Figures

Minimum bid price: $1.00 per share Stockholders’ equity threshold: $2.5 million Consecutive trading days: 20 trading days +1 more

4 metrics

Minimum bid price $1.00 per share Closing bid price maintained above $1.00 for at least 20 consecutive trading days as of July 13, 2026

Stockholders’ equity threshold $2.5 million Minimum stockholders’ equity after acquisition of Psyga Bio Ltd. and equity raise to satisfy Nasdaq Equity Rule 5550(b)(1)

Consecutive trading days 20 trading days Period over which the closing bid price exceeded $1.00 as of July 13, 2026

Monitoring period 1 year Duration of Mandatory Panel Monitor under Nasdaq Listing Rule 5815(d)(4)(B) following the Compliance Letter

Key Terms

Public Interest Concern Rule, Bid Price Rule, Equity Rule, Mandatory Panel Monitor, +1 more

5 terms

Public Interest Concern Rule regulatory

"regained compliance with Nasdaq Listing Rules 5101 (the “Public Interest Concern Rule”)"

Bid Price Rule regulatory

"regained compliance with Nasdaq Listing Rules ... 5550(a)(2) (the “Bid Price Rule”)"

Equity Rule regulatory

"regained compliance with Nasdaq Listing Rules ... 5550(b)(1) (the “Equity Rule”)"

Mandatory Panel Monitor regulatory

"the Company will be subject to a Mandatory Panel Monitor for a period of one year"

A mandatory panel monitor is an independent group tasked with regularly reviewing safety and key results during a clinical trial or regulated program to protect participants and ensure the study is conducted properly. For investors, this matters because the panel can recommend changes, pauses, or early stopping of a trial — actions that can speed up, delay, or quietly derail a program and therefore materially affect a company’s timeline and value, much like a referee whose calls change the outcome of a game.

Delist Determination Letter regulatory

"Instead, Staff will issue a Delist Determination Letter, and the Company will have an opportunity"

A delist determination letter is a formal notice from a stock exchange telling a company it no longer meets listing rules and is facing removal from the exchange. For investors, it signals that the stock may lose its regular trading venue, which can sharply reduce liquidity and visibility—like being forced out of a busy shopping mall into a small flea market—raising the risk of price drops and harder-to-sell shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/21/2026 - 04:06 PM Accepted by SEC EDGAR 07/21/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What did Nasdaq confirm in XTLB’s July 2026 Form 6-K?

Nasdaq confirmed XTL Biopharmaceuticals Ltd. has regained compliance with four listing rules: Public Interest Concern, Periodic Filing, Bid Price, and Equity Rules, as required by a Nasdaq Hearings Panel decision dated May 4, 2026.

How did XTLB satisfy Nasdaq’s Bid Price Rule?

XTL Biopharmaceuticals satisfied the Bid Price Rule by maintaining a closing bid above $1.00 for at least 20 consecutive trading days as of July 13, 2026, meeting Nasdaq’s minimum bid price requirement.

What equity level helped XTLB regain Nasdaq compliance?

Following its acquisition of Psyga Bio Ltd. and an equity raise, XTL Biopharmaceuticals reported at least $2.5 million in stockholders’ equity, helping it comply with Nasdaq Listing Rule 5550(b)(1), known as the Equity Rule.

What ongoing Nasdaq monitoring applies to XTLB after regaining compliance?

The company is subject to a Mandatory Panel Monitor for one year from the Compliance Letter date under Nasdaq Listing Rule 5815(d)(4)(B), meaning its adherence to the Equity Rule will be closely watched during this period.

What happens if XTLB breaches the Nasdaq Equity Rule during the monitoring period?

If XTL Biopharmaceuticals again falls out of compliance with the Equity Rule during the one-year monitoring period, Nasdaq staff will issue a Delist Determination Letter without allowing a cure period, though the company may request a new hearing.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of July, 2026

Commission File Number: 001-36000

XTL Biopharmaceuticals Ltd. 

(Translation of registrant’s name into English)

85 Medinat ha-Yehudim St.

Herzliya, 4676670, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

On July 20, 2026, XTL Biopharmaceuticals Ltd. (the “Company”) received a letter (the “Compliance Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), confirming that the Company has regained compliance with Nasdaq Listing Rules 5101 (the “Public Interest Concern Rule”), 5250(c)(1) (the “Periodic Filing Rule”), 5550(a)(2) (the “Bid Price Rule”), and 5550(b)(1) (the “Equity Rule”), as required by the Nasdaq Hearings Panel’s (the “Panel”) decision dated May 4, 2026.

The Staff’s determination was based on: (i) as of July 13, 2026, the Company having evidenced a closing bid price above $1.00 for at least 20 consecutive trading days; (ii) on June 30, 2026, the Company having filed its Form 20-F for the fiscal year ended December 31, 2025; and (iii) following the consummation of its acquisition of Psyga Bio Ltd. and subsequent equity raise, the Company having a minimum of $2.5 million in stockholders’ equity.

In accordance with Nasdaq Listing Rule 5815(d)(4)(B), the Compliance Letter further provides that the Company will be subject to a Mandatory Panel Monitor for a period of one year from the date of the Compliance Letter. If, within that one-year monitoring period, the Staff finds the Company again out of compliance with the Equity Rule, the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, Staff will issue a Delist Determination Letter, and the Company will have an opportunity to request a new hearing with the Panel.

Cautionary Note Regarding Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this communication that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of the Company and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to (i) the Company’s ability to successfully manage and integrate any joint ventures, acquisitions of businesses, solutions or technologies; (ii) unanticipated operating costs, transaction costs and actual or contingent liabilities; (iii) the ability to attract and retain qualified employees and key personnel; (iv) adverse effects of increased competition on the Company’s future business; (v) the risk that changes in consumer behavior could adversely affect the Company’s business; (vi) the Company’s ability to protect its intellectual property; (vii) local, industry and general business and economic conditions. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 20-F and current reports on Form 6-K filed by the Company with the Securities and Exchange Commission. The Company anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. The Company assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing the Company’s plans and expectations as of any subsequent date.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: July 21, 2026	XTL BIOPHARMACEUTICALS LTD.
	By:	/s/ Noam Band
	Name:	Noam Band
	Title:	Chief Executive Officer

2